A breakthrough moment: McMaster researchers discover new class of antibiotics
Excerpt from the Press Release:
The last time a new class of antibiotics reached the market was nearly three decades ago — but that could soon change, thanks to a discovery by researchers at McMaster University.
A team led by renowned researcher Gerry Wright has identified a strong candidate to challenge even some of the most drug-resistant bacteria on the planet: a new class of antibiotics called lariocidin. The findings were published in the journal Nature on March 26, 2025.
The discovery responds to a critical need for new antimicrobial medicines, as bacteria and other microorganisms evolve new ways to withstand existing drugs. This phenomenon is called antimicrobial resistance — or AMR — and it’s one of the top global public health threats, according to the World Health Organization.
“Our old drugs are becoming less and less effective as bacteria become more and more resistant to them,” explains Gerry Wright, a professor in McMaster’s Department of Biochemistry and Biomedical Sciences and a researcher at the university’s Michael G. DeGroote Institute for Infectious Disease Research. “About 4.5 million people die every year due to antibiotic-resistant infections, and it’s only getting worse.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?